Clovis Oncology Temettü

Temettü kriter kontrolleri 0/6

Clovis Oncology şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.2%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$1.73
Gelecekteki Temettü Verimi	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Clovis Oncology rises on clinical supply agreement with Isotopia

Sep 21

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Sep 12

Clovis Oncology: Needs Some Encouraging Data Quickly

Aug 11

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Aug 10

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Feb 24

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Jan 11

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Dec 30

Clovis Oncology Stock: Only Glimmers Of Hope

Oct 07

Clovis: Compelling With Upcoming Catalysts

Jul 30

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Jun 17

Clovis Oncology and Inovio gain amid Reddit chatter

Jun 09

Clovis Oncology: Another Upcycle Coming

May 08

Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds

May 05

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Mar 17

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 22

Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan

Jan 31

Clovis Oncology: Finally Green Shoots May Be On The Horizon

Jan 29

Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M

Jan 11

What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Dec 31

Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial

Dec 29

Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study

Dec 21

Clovis Oncology existing holder purchases additional $7.5M convertible senior notes

Nov 25

Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance

Nov 09

Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term

Nov 06

Clovis Oncology EPS beats by $0.11, misses on revenue

Nov 05

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CLVS.Q şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CLVS.Q şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Clovis Oncology Piyasaya Karşı Temettü Getirisi

CLVS.Q temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CLVS.Q)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (CLVS.Q) (3 yıla kadar)	0%

Önemli Temettü: CLVS.Q şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CLVS.Q şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CLVS.Q şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CLVS.Q herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Clovis Oncology Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology rises on clinical supply agreement with Isotopia

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Consensus revenue estimates fall by 13%

Clovis Oncology: Needs Some Encouraging Data Quickly

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Clovis Oncology Q2 2022 Earnings Preview

EMA recommends restricted use of Clovis cancer drug

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology climbs 34% as shareholders reject reverse stock split

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Clovis: Shifting Toward Nuclear Medicine

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Clovis Oncology: Forging A Fresh Perspective

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: EPS exceeds analyst expectations

Consensus revenue estimates fall by 18%

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Price target increased to US$6.33

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Price target increased to US$6.33

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Price target increased to US$6.38

Clovis Oncology Stock: Only Glimmers Of Hope

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Price target decreased to US$5.90

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis: Compelling With Upcoming Catalysts

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Clovis Oncology and Inovio gain amid Reddit chatter

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

Clovis Oncology: Another Upcycle Coming

Consensus forecasts updated

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Price target decreased to US$6.35

Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Insider recently sold US$56k worth of stock

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Revenue and earnings beat expectations

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: US$9.36

Executive VP exercised options and sold US$95k worth of stock

Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan

Clovis Oncology: Finally Green Shoots May Be On The Horizon

New 90-day high: US$6.12

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M

What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study